Pfizer and BioNTech work to scale up COVID-19 vaccine production
Pfizer identifies four facilities globally to produce vaccine, while BioNTech will increase production at its German facilities.
Pfizer identifies four facilities globally to produce vaccine, while BioNTech will increase production at its German facilities.
The biotech emerges from stealth mode with two partnerships potentially worth in excess of $2bn.
Regeneron expects an antibody cocktail against coronavirus to be ready for trials in June, plans to utilize entire facility for production.